Page 15 - KIDNEY CANCER

Thoughts and Take Aways

• PFS is great – what about OS?

• Molecular analysis and associated outcomes based on

MET expression pending

• Predictive biomarker?

• SAVOIR study – savolitinib vs sunitinib
1

• PFS 7.0 vs 5.6 HR 0.71, ORR 27% vs 7 %

• Supplants IO combinations in first line?

• Retrospective/case series data suggest IO drugs active 1,2

• PAPMET-2 study design pending – nivo+cabo vs cabo?

1. Chouieri TK et al. JAMA Oncol. 2020 Aug 1;6(8):1247-1255.
2. McGregor BA et al. J Clin Oncol. 2020 Jan 1;38(1):63-70.
3. Graham J et al. J Clin Oncol 39, 2021 (suppl 6; abstr 316)